价格

ASO-1

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS: ASO COUPLED TRANSLATION - UPREGULATION 1 (ACT-UP1) AND USES THEREOF
EP 4671372 A2申请人: ARNATAR THERAPEUTICS INC优先权: 2024
CN
EP
US
WO
9 件公开
COMPOUNDS FOR INHIBITION OF IL-1BETA EXPRESSION
EP 4788811 A1申请人: LEMBA BV优先权: 2023
CN
EP
US
WO
4 件公开
ORAL DELIVERY OF OLIGONUCLEOTIDES
- EP 4326329 A4
  申请人: CIVI BIOPHARMA INC优先权: 2021
  EP
  US
  WO
  3 件公开
- CN 117545509 A
  申请人: CIVI BIOPHARMACEUTICALS CO LTD优先权: 2021
  CN
COMPOUNDS FOR INHIBITING AMANZI
EP 4788812 A1申请人: LEMBA BV优先权: 2023
CN
EP
WO
3 件公开
Lipid nanoparticle compositions for antisense oligonucleotides delivery
US 10307490 B2申请人: UNIV OHIO STATE优先权: 2013
CN
US
3 件公开
Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
CN 104758312 A申请人: KOMINOX INC优先权: 2005
CN
EP
2 件公开
COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY
EP 3837374 A4申请人: BIOGEN MA INC优先权: 2018
EP
US
2 件公开
GROUP OF ANTISENSE OLIGONUCLEOTIDES THAT SPECIFICALLY INHIBIT ANDROGEN RECEPTOR, AND USE THEREOF
WO 2025119007 A1申请人: LNCTAC CO LTD优先权: 2023
CN
WO
2 件公开
ASO FOR PREVENTION AND TREATMENT OF CANCER METASTASIS AND USE THEREOF
WO 2025162482 A1申请人: UNIV ZHEJIANG优先权: 2024
CN
WO
2 件公开
SET OF ANTISENSE OLIGONUCLEOTIDES FOR SPECIFICALLY INHIBITING 5α-REDUCTASE AND APPLICATION THEREOF
WO 2026138433 A1申请人: LNCTAC SUZHOU PHARMACEUTICAL TECH CO LTD优先权: 2024
CN
WO
2 件公开

药物

ASO-1

专利

ORAL DELIVERY OF OLIGONUCLEOTIDES